Introduction: Platelets play a pivotal role in the occurrence of recurrent ischemic events in
coronary artery disease patients who are treated with drug-eluting stents and are on dual …

Although the use of drug-eluting stents (DES) has significantly reduced the rates of ischemic
events in patients with coronary artery disease undergoing percutaneous coronary …

Objectives: This study sought to determine whether there is an ideal level of platelet
reactivity (PR) to optimize safety and efficacy within the large multicenter ADAPT-DES …

Stent thrombosis (ST) is a rare but potentially life-threatening event that can occur following
percutaneous coronary intervention (PCI) with stent implantation. Several factors related to …

Objectives: In this analysis of 2-year outcomes in the ADAPT-DES (Assessment of Dual
AntiPlatelet Therapy with Drug-Eluting Stents) study, the authors sought to examine the …

Background The association of platelet reactivity and clinical outcomes, especially stent
thrombosis, was not so clear. We sought to investigate whether high platelet reactivity affects …

Aim: Although high on-treatment platelet reactivity (HTPR) with dual antiplatelet therapy
(DAPT) correlates with long-term adverse outcomes in patients undergoing percutaneous …

Background The relation between platelet reactivity and stent thrombosis, major bleeding,
and other adverse events after coronary artery implantation of drug-eluting stents has been …

Background Predicting future bleeding events represents an unmet medical need that will
ultimately improve outcomes during dual antiplatelet therapy (DAPT). Although low platelet …

Dual antiplatelet therapy is critical to inhibit platelet reactivity in order to prevent ischemic
reccurences in stented patients. However, studies have observed a variable blockade of the …